Brief: Oculis Phase 3 DIAMOND Trials Miss Primary Endpoint For OCS-01 In Diabetic Macular Edema
29/05/2026 20:01
BRIEF-Oculis Phase 3 DIAMOND Trials Miss Primary Endpoint For OCS-01 In Diabetic Macular Edema May 29 (Reuters) - Oculis Holding AG CR5.F:
OCULIS ANNOUNCES TOPLINE RESULTS FROM DIAMOND PHASE 3 TRIALS WITH OCS-01 IN DIABETIC MACULAR EDEMA
PRIMARY ENDPOINT OF MEAN CHANGE IN BEST CORRECTED VISUAL ACUITY FROM BASELINE TO WEEK 52 IN BOTH PHASE 3 TRIALS WAS NOT MET
WILL NOT PURSUE FDA FILING FOR OCS-1 IN DIABETIC MACULAR EDEMA
SECONDARY ENDPOINT OF RETINAL THICKNESS SHOWED A SUBSTANTIAL AND PERSISTENT REDUCTION WITH OCS-01 VERSUS VEHICLE IN BOTH TRIALS
FINANCIAL POSITION REMAINS STRONG WITH $278 MILLION IN CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS AS OF MARCH 31, 2026
Source text: ID:nGNE6fnn05
Further company coverage: CR5.F
((Reuters.Briefs@thomsonreuters.com;))